Literature DB >> 12882767

Idiopathic and radiation-induced ocular telangiectasia: the involvement of the ATM gene.

Martine Mauget-Faÿsse1, Michèle Vuillaume, Maddalena Quaranta, Norman Moullan, Sandra Angèle, Marlin D Friesen, Janet Hall.   

Abstract

PURPOSE: To investigate whether individuals, with no family history of ataxia telangiectasia (AT), in whom idiopathic or radiation-induced ocular telangiectasia developed are carriers of ATM gene mutations.
METHODS: The ATM cDNA from lymphoblastoid cell lines established from 16 patients with idiopathic retinal or choroidal telangiectasia and 14 patients with radiation-induced telangiectasia after radiotherapy for age-related macular degeneration (AMD) was screened using the restriction endonuclease fingerprinting technique. The frequency of each detected variant was determined in the French population by either a mass spectrometry-based technique or variant-specific endonuclease digestion.
RESULTS: Twenty-one ATM missense alterations, at 10 different sites, 8 of which would result in an amino acid substitution at a conserved position in the ATM protein were found. Four were novel changes, three of which were not detected in the 128 French control subjects screened. Eleven of 16 of the individuals with either idiopathic polypoidal choroidal vasculopathy or juxtafoveolar retinal telangiectasis and 6 of 14 individuals that had choroidal telangiectasis after radiotherapy for AMD carried ATM sequence variants. These latter six individuals had a significantly shorter delay time before the presentation of this vasculopathy compared with those individuals who had a wild-type ATM (11.8 +/- 3.4 months vs. 17.5 +/- 4.5 months, P = 0.024). They had also received a lower average dose of X-rays, although this difference did not reach statistical significance (18.7 +/- 3.9 Gy vs. 23.7 +/- 5.6 Gy, P = 0.09).
CONCLUSIONS: ATM missense variants could confer an AT-like phenotype and influence the formation of retinal and choroidal vascular abnormalities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12882767     DOI: 10.1167/iovs.02-1269

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Demographic features of idiopathic macular telangiectasia in Japanese patients.

Authors:  Ichiro Maruko; Tomohiro Iida; Yukinori Sugano; Akira Ojima; Hiroshi Oyamada; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2012-01-06       Impact factor: 2.447

2.  A role for vascular deficiency in retinal pathology in a mouse model of ataxia-telangiectasia.

Authors:  Dorit Raz-Prag; Ronit Galron; Niva Segev-Amzaleg; Arieh S Solomon; Yosef Shiloh; Ari Barzilai; Dan Frenkel
Journal:  Am J Pathol       Date:  2011-07-19       Impact factor: 4.307

3.  Apelin is required for non-neovascular remodeling in the retina.

Authors:  Jenny A G McKenzie; Marcus Fruttiger; Sabu Abraham; Clemens A K Lange; Jay Stone; Pranita Gandhi; Xiaomeng Wang; James Bainbridge; Stephen E Moss; John Greenwood
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

4.  Transcriptomic Analysis of circRNAs in the Peripheral Blood of Nonarteritic Anterior Ischemic Optic Neuropathy.

Authors:  Jinshan Suo; Xinling Xu; Haoyan Xu; Naifang Hou; Jiaming Zhang; XIao Han; Yanwen Zheng; Xinling Wang; Xiao Han
Journal:  Biomed Res Int       Date:  2020-11-26       Impact factor: 3.411

5.  ATM localization and gene expression in the adult mouse eye.

Authors:  Julia Leemput; Christel Masson; Karine Bigot; Abdelmounaim Errachid; Anouk Dansault; Alexandra Provost; Stéphanie Gadin; Said Aoufouchi; Maurice Menasche; Marc Abitbol
Journal:  Mol Vis       Date:  2009-02-20       Impact factor: 2.367

6.  ATM polymorphisms as risk factors for prostate cancer development.

Authors:  S Angèle; A Falconer; S M Edwards; T Dörk; M Bremer; N Moullan; B Chapot; K Muir; R Houlston; A R Norman; S Bullock; Q Hope; J Meitz; D Dearnaley; A Dowe; C Southgate; A Ardern-Jones; D F Easton; R A Eeles; J Hall
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.